Illumina Launches TruSight One Sequencing Panel

  Illumina Launches TruSight One Sequencing Panel

4,800 Gene Comprehensive Panel Expands, Streamlines, and Simplifies Sequencing
                                  Portfolios

Business Wire

SAN DIEGO -- October 7, 2013

Illumina, Inc. (NASDAQ:ILMN) today announced the launch of the TruSight One
Sequencing Panel, the industry’s broadest sequencing panel that targets 4,813
genes with known associated clinical phenotypes. Clinical research
laboratories can use this panel to expand existing menus, streamline
workflows, or create an entire portfolio of sequencing options, with benefits
including increased productivity, reduced handling errors, and decreased
costs.

The power of the TruSight One Sequencing Panel is enhanced by Illumina’s
user-friendly VariantStudio analysis and reporting software. To coincide with
the introduction of the TruSight One Sequencing Panel, VariantStudio will
offer new features that expand annotation and filtering capabilities. These
features include support for enabling family-based filtering (mother, father,
child, and siblings), providing variant classifications, and generating
ready-to-use reports. In addition, the TruSight One Sequencing Panel can be
used to create dozens of “virtual subpanels” to fit the needs of any clinical
researcher seeking to understand the genetic basis of disease.

“Illumina is moving in the direction of one simple workflow which will
drastically reduce the turnaround time from sample-to-report,” said Matt
Posard, Senior Vice President and General Manager of Illumina’s Translational
and Consumer Genomics business. “With the TruSight One Sequencing Panel and
enhancements to VariantStudio, Illumina is providing clinical researchers with
a simple, cost-effective solution that replaces small sequencing panels with a
single robust platform.”

“Our genetics laboratory handles increasing numbers of requests to sequence a
wide range of genes believed to be causing inherited disorders,” said Stephen
Abbs, Director of Genetics Laboratories, Cambridge University Hospitals NHS
Foundation Trust. “The broad coverage and high performance of the TruSight One
Sequencing Panel allow us to perform these analyses using a streamlined
laboratory workflow, as well as to offer a comprehensive, high-quality
sequencing service.”

The TruSight One Sequencing Panel is now shipping. For more information, visit
www.illumina.com/PowerOfOne.

AboutIllumina

Illumina(www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.